Marpai (MRAI) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenues were $5.4 million, down 27% year-over-year, primarily due to industry and customer turnover and a focus on higher-margin clients.

• Operating expenses improved by 33% to $7.7 million, driving a 45% reduction in operating loss to $2.3 million compared to Q1 2024.

• Net loss improved by 29% year-over-year to $3.1 million, with EPS at $(0.21), a $0.25 per share improvement.

• Leadership strengthened with the appointment of Dallas Scrip as COO and President of MarpaiRx, effective June 2, 2025.

• The company is exploring strategic alternatives, including potential sale, merger, or investment.

Financial highlights

• Net revenues: $5.4 million for Q1 2025, down $2.0 million year-over-year.

• Operating expenses: $7.7 million, down $3.8 million year-over-year.

• Operating loss: $2.3 million, improved by $1.8 million year-over-year.

• Net loss: $3.1 million, improved from $4.3 million year-over-year.

• Cash and cash equivalents: $0.7 million as of March 31, 2025.

Outlook and guidance

• Management targets profitability and positive cash flow by year-end 2025, supported by cost reductions and a strong business pipeline.

• New client wins expected to drive revenue growth in the second half of 2025, with updates on the January 2026 sales pipeline after Q3 2025.

• Management projects need for additional capital to fund operations until revenue scales to self-sufficiency.

• Substantial doubt exists about ability to continue as a going concern over the next 12 months.